Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 5/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 4/20 | 0.32 |
| ▸ | AKT2 | P31751 | 3/20 | 0.32 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.30 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198761 | 0.89 | TLR4 (0.52) | TLR4SMPD1AKT1AKT2AKT3 | |
| SCHEMBL4201320 | 0.85 | TLR4 (0.50) | TLR4 | |
| SCHEMBL4195266 | 0.85 | TLR4 (0.50) | TLR4 | |
| SCHEMBL4201319 | 0.85 | TLR4 (0.50) | TLR4 | |
| SCHEMBL12371527 | 0.85 | TLR4 (0.41) | TLR4 | |
| SCHEMBL12371534 | 0.84 | TLR4 (0.41) | TLR4 | |
| SCHEMBL13792001 | 0.84 | TLR4 (0.54) | TLR4 | |
| SCHEMBL10042153 | 0.84 | TLR4 (0.62) | TLR4 | |
| SCHEMBL13791956 | 0.84 | TLR4 (0.62) | TLR4 | |
| SCHEMBL12763043 | 0.84 | TLR4 (0.54) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994154-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | Ersai R&D Management Co., Ltd. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-09-09 | — | — | US | disclosed |
| US-7737129-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | EISAI CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | LIPG, FUT6, UGCG | TLR4 94/4885SMPD1 140/4885AKT1 1947/4885 |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | LIPG, FUT6, UGCG | TLR4 94/4885SMPD1 140/4885AKT1 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.